V-Learning: Targeting MET with an emphasis on NSCLC

Solange Peters, Lecturer of the new V-learing module on MET

ESMO’s strategic goal is to continually develop on-line educational tools for professionals in the field of Medical Oncology and foster new challenging CME opportunities for ESMO Members

What is ESMO V-Learning?

Recent scientific discoveries in cancer and signalling pathways for which an update of knowledge is needed and for its complete understanding additional video material is beneficialScience in cancer is moving rapidly and to keep in pace with rapid progresses, more complete understanding of molecular biology/pathology, or technological advances is needed. The V-Learning platform is ideal to present such novelties end enhance understanding of clinicians by additional visual components beyond classical slide presentationIt present in more realistic way what’s going on at the cancer cell level and provide in more details the mechanistic aspects involved in different cancer processes

Relatris‘s insight:

The European Society for Medical Oncologists has many great resources for (continued) education. The newest family member are V-Learning lectures: slides and video sections combined (with questionnaires). Video lectures with slides are the format of the widely popular MOOCs, providing a more personal way of teaching than just hearing a voice from the off while seeing some slides. This integration of new trends in education into their continued education lectures is an innovative way of ESMO to further improve their programms.

See on www.esmo.org

Advertisements

‘Game changing’ cancer database pushes fight against disease forward

See on Scoop.itoncoTools

The world’s largest cancer database will be launched in the UK today, in what experts are calling a “game-changing” stride forward in the fight against the disease.

Millions of patient records containing detailed information on individual cancers and how they have been treated will be available to specialists around the country, paving the way for highly personalised treatment of individual patients.

“This is game-changing,” Jem Rashbass, who led the project at Public Health England, told The Times. “This puts us at the forefront of cancer care for the next two decades.”

“In effect every cancer patient has a rare disease that is different in some way from another cancer. This allows us to carry out refined searches to see how other tumours have responded to identify the optimum treatment as early as possible.”

Relatris‘s insight:

Great to have such a database. The big challenge will be to use it meaningfully, so to not only have good search algorithms, but to draw the right conclusions out of the results. Then, this will be a powerful tool!

See on www.independent.co.uk